Germline and tumor genetics to understand glioma risk and patient outcomes
Official title: Using germline and somatic genetics to elucidate glioma risk and improve patient outcomes
Funded at Mayo Clinic Rochester · NIH-11397799 · Data updated 2026-11-12
A Mayo Clinic team will study how inherited and tumor DNA variants relate to glioma risk and how this information could improve care for adults with brain tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | August 18, 2025 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $469,453 |
| NIH project number | 5R01CA298083-02 |
| Project ID | NIH-11397799 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with brain tumors (glioma) who may undergo genomic profiling as part of standard care.
✕Less likely to help
Patients without access to genomic testing or those whose tumors do not harbor the studied variants may see limited or no benefit.
What this research studies
This project will analyze germline and somatic genetic variants in adults with glioma using advanced sequencing and data deconvolution techniques. By combining bulk RNA data, single-cell sequencing, and epigenetic information, researchers aim to map how inherited risk variants interact with tumor alterations. The goal is to develop polygenic risk models and insights that could guide prognosis and future therapies. The work focuses on improving understanding of glioma biology to support better patient outcomes.
Why it matters
Potential benefit: If successful, patients could receive more personalized risk assessment and tailored treatment approaches based on their genetic profile.
How similar studies have gone: Previous studies have linked germline variants to glioma risk, with ongoing research expanding understanding through integrated genomic analyses.
Where this research is happening
-
Mayo Clinic Rochester
Rochester, United States Active
Researchers
- Principal investigator: Eckel Passow, Jeanette E — Mayo Clinic Rochester
- Study coordinator: Eckel Passow, Jeanette E
Related research
Other NIH-funded projects on the same topics.
-
Next‑gen oncolytic virus therapy for glioblastoma targeting AKT and ERK
A new cancer therapy using an engineered oncolytic virus to fight glioblastoma by blocking AKT/ERK signals and boosting the body’s immune response, with potential to reduce seizures and improve quality of life.
-
Bone marrow immune cells and glioma progression in teens and young adults
A study in adolescents and young adults with brain tumors looks at how immune cells from bone marrow may influence the progression from low-grade to high-grade gliomas.
-
How RNA Splicing Might Shape Glioma Cell States and Therapy Response
A small NIH-funded project will study how alternative RNA splicing influences glioma cell identities and treatment resistance in patient-derived cells.
-
Liquid biopsy for monitoring high-grade glioma using patient-specific DNA junctions
A Mayo Clinic team tests a blood test that looks for unique tumor DNA pieces in glioblastoma patients to monitor disease without frequent scans.
-
Deciphering how a brain cell pH helper influences glioma growth
A study is exploring whether a brain cell pH regulator (Slc4a4) affects the growth and blood vessel changes of malignant glioma to identify new angles for treatment.
-
Predicting how gene therapy spreads in glioblastoma after surgery to improve treatment coverage
This project uses a gene therapy that helps radiation work better against glioblastoma and builds computer models to predict where the therapy reaches after surgical tumor removal.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.